AdV-tk + Valacyclovir Therapy in Combination With Surgery and Chemoradiation for Pancreas Cancer (PaTK01).
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2015
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Advantagene
- 10 Jun 2017 Biomarkers information updated
- 28 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record
- 24 Feb 2015 Planned End Date changed from 1 May 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov record.